Portage Biotech is focused on developing innovative immuno-oncology therapies aimed at enhancing treatment responses and improving the quality of life for cancer patients. The company has established a diverse portfolio of five drug platforms, which have yielded ten novel assets targeting various cancer resistance pathways. Their approach emphasizes the identification and combination of novel therapeutic assets, leveraging a strong industry network and proven practices from experienced drug discovery professionals. This strategy aims to de-risk early clinical development through efficient capital management and scientific oversight, allowing Portage to continuously evaluate and select the most promising candidates for advancement.

Among the key technologies in Portage's pipeline are the iNKT engagers, specifically PORT-2 and PORT-3, which activate both the innate and adaptive immune systems to target tumors that may not respond to traditional checkpoint inhibitors. PORT-2 is designed to enhance the immune response in patients with non-small cell lung cancer and melanoma, while PORT-3 combines the iNKT engager with specific tumor antigens to improve treatment efficacy. Additionally, Portage is developing the PORT-4 platform, which focuses on co-formulating combination therapies into a single delivery system, and the PORT-5 platform, which utilizes virus-like particles to activate the STING pathway for systemic administration. These innovative approaches aim to create more effective treatment options for patients with limited responses to existing therapies.

United States

Portage Biotech is a clinical-stage immuno-oncology company with a team of scientists, clinicians, and pharma-experienced executives who have a long history of success, collectively contributing to five oncology drug approvals. The company is focused on advancing multi-targeted therapies with the mission to expand the number of treatment options for cancer patients.

Portage Biotech

Company Details